Other Viruses Citation List:
May 14 - May 27, 2010
Hepatitis C Virus
1. The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole Is Highly Synergistic with HCV Protease Inhibitors.
Einav S, Sobol HD, Gehrig E, Glenn JS.
J Infect Dis. 2010 May 20. [Epub ahead of print]; PMID[20486856].
[Pubmed]. OV_0514-052710.
2. S-Aryltriazole acyclonucleosides: Synthesis and biological evaluation against hepatitis C virus.
Liu Y, Xia Y, Li W, Cong M, Maggiani A, Leyssen P, Qu F, Neyts J, Peng L.
Bioorg Med Chem Lett. 2010 Apr 28. [Epub ahead of print]; PMID[20483607].
[Pubmed]. OV_0514-052710.
Epstein Barr Virus
3.Chemopreventive properties of phytosterols and maslinic acid extracted from Coleus tuberosus in inhibiting the expression of EBV early-antigen in Raji cells.
Mooi LY, Wahab NA, Lajis NH, Ali AM.
Chem Biodivers. 2010 May;7(5):1267-75; PMID[20491082].
[Pubmed]. OV_0514-052710.
Citations from the ISI Web of Knowledge Listings for O.I.
4. Discovery of a Novel, Potent Flavonoid Inhibitor of HCV RNA-Dependent RNA Polymerase. Ahmed-Belkacem, A., R. Brillet, C. Pallier, C. Wychowski, J.F. Guichou, and J.M. Pawlotsky. Journal of Hepatology. 52: p. S288-S288; ISI[000277018001365].
[WOS]. OV_0514-052710.
5. Inhibition of HCV NS3 Serine Protease by the Flavanoid Quercetin. Bachmetov, L., R. Zemel, M. Gal-Tanamy, M. Vorobeychik, I. Benhar, and R. Tur-Kaspa. Journal of Hepatology. 52: p. S288-S288; ISI[000277018001366].
[WOS]. OV_0514-052710.
6. Fluvastatin Provides Syngergistic Anti-HCV Activity When Combined with a Polymerase Inhibito. 2-CMA, In Vitro. Bader, T. and Z. Zhang. Journal of Hepatology. 52: p. S288-S289; ISI[000277018001367].
[WOS]. OV_0514-052710.
7. MK-5172: A Novel HCV NS3/4A Protease Inhibitor with Potent Activity Against Known Resistance Mutants. Carroll, S., J. McCauley, S. Ludmerer, S. Harper, V. Summa, M. Rowley, M. Rudd, P. Coleman, N. Liverton, J. Butcher, C. McIntyre, J. Romano, K. Bush, M. Ferrara, B. Crescenzi, A. Petrocchi, M. Difilippo, C. Burlein, J. Dimuzio, D. Graham, C. McHale, M. Stahlhut, A. Gates, C. Fandozzi, N. Trainor, D. Hazuda, J. Vacca, and D. Olsen. Journal of Hepatology. 52: p. S17-S17; ISI[000277018000040].
[WOS]. OV_0514-052710.
8. In Vivo and In Vitro Resistance to Silibinin, a Component of Silymarin and Potent Inhibitor of HCV Replication. Chevaliez, S., A. Ahmed-Belkacem, A. Soulier, K. Zinober, T.M. Scherzer, R. Brillet, P. Ferenci, and J.M. Pawlotsky. Journal of Hepatology. 52: p. S289-S290; ISI[000277018001370].
[WOS]. OV_0514-052710.
9. Identification of a Class of HCV Inhibitors Directed Against the Nonstructural Protein NS4B. Cho, N.J., H. Dvory-Sobol, C. Lee, S.J. Cho, P. Bryson, M. Masek, M. Elazar, C.W. Frank, and J.S. Glenn. Science Translational Medicine. 2(15); ISI[000277264100002].
[WOS]. OV_0514-052710.
10. Discovery of Potent and Selective Inhibitors of Hepatitis C Virus (HCV) Entry with Distinct Mechanisms of Action. Coburn, G.A., A.Q. Han, J.D. Murga, J.M. de Muys, D.N. Fisch, D. Paul, S. Moorji, K.P. Provoncha, Y. Rotshteyn, D. Qian, P.J. Maddon, and W.C. Olson. Journal of Hepatology. 52: p. S50-S50; ISI[000277018000113].
[WOS]. OV_0514-052710.
11. Identification and Characterization of PPL-461, a Potent and Selective HCV NS5A Inhibitor with Activity Against All HCV Genotypes. Colonno, R., E. Peng, M. Bencsik, N. Huang, M. Zhong, A. Huq, Q. Huang, J. Williams, and L. Li. Journal of Hepatology. 52: p. S14-S15; ISI[000277018000034].
[WOS]. OV_0514-052710.
12. Ritonavir Boosting of Low Dose RG7227/ITMN-191, HCV NS3/4A Protease Inhibitor, Results in Robust Reduction in HCV RNA at Lower Exposures than Provided by Unboosted Regimens. Gane, E., R. Rouzier, C. Stedman, A. Wiercinska-Drapalo, A. Horban, L. Chang, Y. Zhang, P. Sampeur, I. Najera, N. Shulman, P. Smith, and J. Tran. Journal of Hepatology. 52: p. S16-S17; ISI[:000277018000039].
[WOS]. OV_0514-052710.
13. Resistance Selection Following 15 Days of Monotherapy with SCY-635 a Non-Immunosuppressive Cyclophilin Inhibitor with Potent Anti-HCV Activity. Hopkins, S., S. Mosier, R. Harris, P. Kowalczyk, and Z. Huang. Journal of Hepatology. 52: p. S15-S15; ISI[000277018000035].
[WOS]. OV_0514-052710.
14. Combination of TMC435 with Two Novel NS5B Inhibitors Increases Anti HCV Activity and Reuslts in a Higher Genetic Barrier In Vitro. Lenz, O., J.M. Berke, H. de Kock, P. van Remoortere, O. Nyanguile, S. Vendeville, T. Jonckers, P. Raboisson, K. Simmen, G. Fanning, and T.I. Lin. Journal of Hepatology. 52: p. S295-S296; ISI[000277018001385].
[WOS]. OV_0514-052710.
15. Identification and Preclinical Profile of the Novel HCV N53 Protease Inhibitor BMS-650032. McPhee, F. Journal of Hepatology. 52: p. S296-S296; ISI[000277018001387].
[WOS]. OV_0514-052710.
16. Naringenin Inhibits the Assembly and Long-Term Production of Infectious Hepatitis C Virus (HCV) Particles Through a PPAR-Mediated Mechanism. Nahmias, Y., S.J. Polyak, and R.T. Chung. Journal of Hepatology. 52: p. S297-S297; ISI[000277018001389].
[WOS]. OV_0514-052710.
17. Modifications of C-2 on the pyrroloquinoline template aimed at the development of potent herpesvirus antivirals with improved aqueous solubility. Nieman, J.A., S.K. Nair, S.E. Heasley, B.L. Schultz, H.M. Zerth, R.A. Nugent, K. Chen, K.J. Stephanski, T.A. Hopkins, M.L. Knechtel, N.L. Oien, J.L. Wieber, and M.W. Wathen. Bioorganic & Medicinal Chemistry Letters. 20(10): p. 3039-3042; ISI[000277246300006].
[WOS]. OV_0514-052710.
18. Inhibition of hepatitis C virus replication by single-stranded RNA structural mimics. Smolic, R., M. Smolic, J.H. Andorfer, C.H. Wu, R.M. Smith, and G.Y. Wu. World Journal of Gastroenterology. 16(17): p. 2100-2108; ISI[000277444600005].
[WOS]. OV_0514-052710.
19. Nonsulfated, Cinnamic Acid-Based Lignins are Potent Antagonists of HSV-1 Entry into Cells. Thakkar, J.N., V. Tiwari, and U.R. Desai. Biomacromolecules. 11(5): p. 1412-1416; ISI[000277355800036].
[WOS]. OV_0514-052710.
20. Enhanced In Vitro Antiviral Activity of ANA598 in Combination with Other Anti-HCV Agents Support Combination Treatment. Thompson, P.A., R.E. Showalter, R.A. Patel, and J.R. Appleman. Journal of Hepatology. 52: p. S262-S262; ISI[000277018001299].
[WOS]. OV_0514-052710.
21. Effect of oxymatrine on the replication cycle of hepatitis B virus in vitro. World Journal of Gastroenterology. Xu, W.S., K.K. Zhao, X.H. Miao, W. Ni, X. Cai, R.Q. Zhang, and J.X. Wang. 16(16): p. 2028-2037; ISI[000277187600013].
[WOS]. OV_0514-052710.